IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis
Xu, L-P; Liu, K-Y; Liu, D-H; Chen, H.; Han, W.; Chen, Y-H; Wang, Y.; Huang, X-J
关键词Pbsct Haploidentical Hematological Malignancies
刊名BONE MARROW TRANSPLANTATION
2010-06-01
DOI10.1038/bmt.2009.311
45期:6页:985-992
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]DONOR LYMPHOCYTE INFUSION ; BONE-MARROW ; HEMATOLOGICAL MALIGNANCIES ; RELAPSE ; PROPHYLAXIS ; RECIPIENTS ; DEPLETION ; DISEASE
英文摘要

The purpose of this study was to investigate the efficacy and feasibility of unmanipulated haploidentical PBSCT for the treatment of acute leukemia (AL). This study compares the clinical outcomes of high-risk AL patients who received PBSCs harvested from family members sharing at least one common haplotype to outcomes of high-risk AL patients who received a mixture of G-CSF-primed BM (G-BM) and peripheral blood (G-PB) harvests. The results show that PBSCT achieved inferior cumulative myeloid engraftment at 30 days after transplant (89.9+/-10.1% vs 100%; P=0.04), with lower cumulative incidence of grade II-IV acute GVHD (aGVHD) (37.1+/-16.5% vs 63.2+/-6%; P=0.058) compared with G-BM/G-PB transplant. However, both transplant protocols had similar rates of 2-year relapse (29.6+/-17.1% vs 34.0+/-5.7%; P=0.954), and PBSCT produced a higher incidence of 2-year non-leukemic mortality (62.5+/-14.8% vs 35.1+/-5.1%; P=0.014), as well as lower rates of overall (26.8+/-12.3% vs 43.2+/-5.0%; P=0.052) and disease-free survival (26.8+/-12.3% vs 42.4+/-5.0%; P=0.071) compared with G-BM/G-PB transplant. These results suggest that haploidentical HSCT is an option for patients with AL who urgently need a graft and do not have matched sibling donors. PBSCT is potentially inferior to G-BM/G-PB transplant, and improvements should be made before PBSCT becomes a routine in unmanipulated mismatched/haploidentical transplant settings. Bone Marrow Transplantation (2010) 45, 985-992; doi:10.1038/bmt.2009.311; published online 9 November 2009

语种英语
WOS记录号WOS:000278573600005
项目编号30725038 ; IRT0702 ; 2006AA02Z4A0
资助机构National Outstanding Young Scientists&prime ; Foundation of China ; Program for Innovative Research Team in University ; HI-Tech Research Development Program of China 863
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54944
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Dept Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Xu, L-P,Liu, K-Y,Liu, D-H,et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis[J]. BONE MARROW TRANSPLANTATION,2010,45(6):985-992.
APA Xu, L-P.,Liu, K-Y.,Liu, D-H.,Chen, H..,Han, W..,...&Huang, X-J.(2010).The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.BONE MARROW TRANSPLANTATION,45(6),985-992.
MLA Xu, L-P,et al."The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis".BONE MARROW TRANSPLANTATION 45.6(2010):985-992.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xu, L-P]的文章
[Liu, K-Y]的文章
[Liu, D-H]的文章
百度学术
百度学术中相似的文章
[Xu, L-P]的文章
[Liu, K-Y]的文章
[Liu, D-H]的文章
必应学术
必应学术中相似的文章
[Xu, L-P]的文章
[Liu, K-Y]的文章
[Liu, D-H]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。